Copyright
©The Author(s) 2016.
World J Gastrointest Endosc. Apr 10, 2016; 8(7): 338-343
Published online Apr 10, 2016. doi: 10.4253/wjge.v8.i7.338
Published online Apr 10, 2016. doi: 10.4253/wjge.v8.i7.338
SEMS (n = 30) | SEPS (n = 13) | P value | |
Mean age (yr ± SD) | 59.6 ± 14.87 | 61.7 ± 9.95 | 0.645 |
% male | 83.3% | 76.9% | 0.681 |
Race/ethnicity, n (%) | AA: 9 (30%) | AA: 6 (46%) | 0.704 |
nHw: 18 (60%) | nHw: 7 (54%) | ||
Other: 3 (10%) | Other: 0 | ||
Malignant esophageal lesion, n (%) | 25 (83.3%) | 10 (76.9%) | 0.681 |
Esophageal lesion location, n (%) | Upper third: 0 | Upper third: 1 (7.7%) | 0.15 |
Middle third: 9 (30%) | Middle third: 6 (46.2%) | ||
Lower third: 21 (70%) | Lower third: 6 (46.2%) | ||
Comorbid diseases, n (%) | HTN: 16 (53.3%) | HTN: 6 (46.2%) | 0.747 |
CAD: 7 (23.3%) | CAD: 2 (15.4%) | 0.699 | |
COPD: 5 (16.7%) | COPD: 1 (7.7%) | 0.649 | |
DM: 11 (36.7%) | DM: 3 (23.1%) | 0.491 |
- Citation: McGaw C, Alkaddour A, Vega KJ, Munoz JC. Stent type used does not impact complication rate or placement time but can decrease treatment cost for benign and malignant esophageal lesions. World J Gastrointest Endosc 2016; 8(7): 338-343
- URL: https://www.wjgnet.com/1948-5190/full/v8/i7/338.htm
- DOI: https://dx.doi.org/10.4253/wjge.v8.i7.338